Focusing on frequent ASXL1 mutations in myeloid neoplasms, and considering rarer ASXL2 and ASXL3 mutations

"Focusing on frequent ASXL1 mutations in myeloid neoplasms, and considering rarer ASXL2 and ASXL3 mutations." Current Medical Research and Opinion, 33(4), pp. 781–782

Transparency

Funding

This editorial was not funded.

Declaration of financial/other relationships

J.S.O. and R.S.O. have disclosed that they have no significant relationships with or financial interests in any commercial companies related to this study or article.

CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.